FLNA
Filana Therapeutics, Inc.
NASDAQ: FLNA · HEALTHCARE · BIOTECHNOLOGY
$1.44
-7.69% today
Updated 2026-04-29
Market cap
$77.78M
P/E ratio
—
P/S ratio
2.54x
EPS (TTM)
$-1.88
Dividend yield
—
52W range
$1 – $5
Volume
0.5M
Filana Therapeutics, Inc. (FLNA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
2 of 8
Last 8 quarters
Avg EPS surprise
+15.9%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+54.7%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.7%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.5%
2025-11-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.26 | +13.3% | $2.38 | $2.38 | +0.0% |
| 2025-11-12 | $-0.22 | +18.5% | $3.11 | $2.94 | -5.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.30 | $-0.26 | +13.3% | — | — |
| 2025-09-30 | $-0.27 | $-0.22 | +18.5% | — | — |
| 2025-06-30 | — | $-0.92 | — | — | — |
| 2025-03-31 | — | $-0.48 | — | — | — |
| 2024-12-31 | — | $-0.57 | — | — | — |
| 2024-09-30 | — | $-0.58 | — | — | — |
| 2024-06-30 | — | $0.13 | — | — | — |
| 2024-03-31 | — | $-0.43 | — | — | — |
| 2023-12-31 | — | $-0.50 | — | — | — |
| 2023-09-30 | — | $-0.61 | — | — | — |
| 2023-06-30 | — | $-0.63 | — | — | — |
| 2023-03-31 | — | $-0.58 | — | — | — |
| 2022-12-31 | — | $-0.47 | — | — | — |
Frequently asked questions
Has Filana Therapeutics, Inc. beaten earnings estimates?
Filana Therapeutics, Inc. has beaten Wall Street EPS estimates in 2 of its last 8 quarterly reports, with an average EPS surprise of +15.9% over the last 2 quarters.
How does FLNA stock react to earnings?
FLNA stock has moved an average of -2.7% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.